Browse > Article

Inhibition of ${\beta}-amyloid_{1-40}$ Peptide Aggregation and Neurotoxicity by Citrate  

Park, Yong-Hoon (Inam Neuroscience Research Center College of Medicine, Wonkwang University)
Kim, Young-Jin (Department of Neurology, Sanbon Medical Center, College of Medicine, Wonkwang University)
Son, Il-Hong (Inam Neuroscience Research Center College of Medicine, Wonkwang University)
Yang, Hyun-Duk (Inam Neuroscience Research Center College of Medicine, Wonkwang University)
Publication Information
The Korean Journal of Physiology and Pharmacology / v.13, no.4, 2009 , pp. 273-279 More about this Journal
Abstract
The accumulation of ${\beta}$-amyloid (A${\beta}$) aggregates is a characteristic of Alzheimer's disease (AD). Furthermore, these aggregates have neurotoxic effects on cells, and thus, molecules that inhibit A${\beta}$ aggregate formation could be valuable therapeutics for AD. It is well known that aggregation of A${\beta}$ depends on its hydrophobicity, and thus, in order to increase the hydrophilicity of A${\beta}$, we considered using citrate, an anionic surfactant with three carboxylic acid groups. We hypothesized that citrate could reduce hydrophobicity and increase hydrophilicity of A${\beta}_{1-40}$ molecules via hydrophilic/electrostatic interactions. We found that citrate significantly inhibited A${\beta}_{1-40}$ aggregation and significantly protected SH-SY5Y cell line against A${\beta}_{1-40}$ aggregates-induced neurotoxicity. In details, we examined the effects of citrate on A${\beta}_{1-40}$ aggregation and on A${\beta}_{1-40}$ aggregates-induced cytotoxicity, cell viability, and apoptosis. Th-T assays showed that citrate significantly inhibited A${\beta}_{1-40}$ aggregation in a concentration-dependent manner (Th-T intensity: from 91.3% in 0.01 mM citrate to 82.1% in 1.0 mM citrate vs. 100.0% in A${\beta}_{1-40}$ alone). In cytotoxicity and viability assays, citrate reduced the toxicity of A${\beta}_{1-40}$ in a concentration-dependent manner, in which the cytotoxicity decreased from 107.5 to 102.3% as compared with A${\beta}_{1-40}$ aggregates alone treated cells (127.3%) and the cell viability increased from 84.6 to 93.8% as compared with the A${\beta}_{1-40}$ aggregates alone treated cells (65.3%). Furthermore, Hoechst 33342 staining showed that citrate (1.0 mM) suppressed A${\beta}_{1-40}$ aggregates-induced apoptosis in the cells. This study suggests that citrate can inhibit A${\beta}_{1-40}$ aggregation and protect neurons from the apoptotic effects of A${\beta}_{1-40}$ aggregates. Accordingly, our findings suggest that citrate administration should be viewed as a novel neuroprotective strategy for AD.
Keywords
Citrate; Alzheimer's disease; ${\beta}$-amyloid; Aggregation; Apoptosis;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Barrow CJ, Zagorski MG. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 253: 179−182, 1991   DOI   PUBMED   ScienceOn
2 Brus L. Noble metal nanocrystals: plasmon electron transfer photochemistry and single-molecule raman spectroscopy. Acc Chem Res 41: 1742−1749, 2008   DOI   PUBMED   ScienceOn
3 Cao M, Han Y, Wang J, Wang Y. Modulation of fibrillogenesis of amyloid $\beta$ (1-40) peptide with cationic gemini surfactant. J Phys Chem B 111: 13436−13443, 2007   DOI   PUBMED   ScienceOn
4 Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 5: 677−685, 2004   DOI   PUBMED   ScienceOn
5 Hensley K, Carney JM, Mattson MP, Aksenova MV, Harris ME, Wu JF, Floyd RA, Butterfield DA. A model for $\beta$-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 91: 3270−3274, 1994   DOI   ScienceOn
6 Ji SR, Wu Y, Sui SF. Study of beta-amyloid peptide (Abeta40) insertion into phospholipid membranes using monolayer technique. Biochemistry (Mosc) 67: 1283−1288, 2002   DOI   PUBMED   ScienceOn
7 Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R. 3D structure of Alzheimer's amyloid-$\beta$ (1-42) fibrils. Proc Natl Acad Sci USA 102: 17342−17347, 2005   DOI   ScienceOn
8 McConnell S, Riggs J. Alzheimer's research: can it help save our nation's entitlement programs? Alzheimer Dementia 1: 84−86, 2005   DOI   ScienceOn
9 Pallitto MM, Ghanta J, Heinzelman P, Kiessling LL, Murphy RM. Recognition sequence design for peptidyl modulators of beta- amyloid aggregation and toxicity. Biochemistry 38: 3570−3578, 1999   DOI   PUBMED   ScienceOn
10 Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. Aggregation related toxicity of synthetic beta-amyloid protein in hippocampal cultures, Eur J Pharmacol 207: 367−368, 1991   DOI   PUBMED   ScienceOn
11 Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253−265, 1995   DOI   PUBMED   ScienceOn
12 Puntel RL, Roos DH, Grotto D, Garcia SC, Nogueira CW, Rocha JB. Antioxidant properties of Krebs cycle intermediates against malonate pro-oxidant activity in vitro: a comparative study using the colorimetric method and HPLC analysis to determine malondialdehyde in rat brain homogenates. Life Sci 81: 51−62, 2007   DOI   PUBMED   ScienceOn
13 Sabate R, Gallardo M, Estelrich J. An autocatalytic reaction as a model for the kinetics of the aggregation of beta-amyloid. Biopolymers 71: 190−195, 2003   DOI   PUBMED   ScienceOn
14 Watanabe K, Segawa T, Nakamura K, Kodaka M, Konakahara T, Okuno H. Identification of the molecular-interaction site of amyloid beta peptide by using a fluorescence assay. J Pept Res 58: 342−346, 2001   DOI   ScienceOn
15 Wood SJ, MacKenzie L, Maleeff B, Hurle MR, Wetzel R. Selective inhibition of Abeta fibril formation. J Biol Chem 271: 4086−4092, 1996a   DOI   PUBMED
16 Yang HD, Son IH, Lee SS, Park YH. Protective effect of citrate against A$\beta$-induced neurotoxicity in PC12 cells. Mol Cell Toxicol 4: 157−163, 2008
17 Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741−766, 2001   PUBMED   ScienceOn
18 Bokvist M, Lindstrom F, Watts A, Grobner G. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol 335: 1039−1049, 2004   DOI   PUBMED   ScienceOn
19 Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr, Wang Q, Roach AH, Thompson LA, Spitz SM, Higaki JN, Prakash SR, Combs AP, Copeland RA, Arneric SP, Hartig PR, Robertson DW, Cordell B, Stern AM, Olson RE, Zaczek R. Presenilin-1 and -2 are molecular targets for gamma- secretase inhibitors. J Biol Chem 275: 34086−34091, 2000   DOI   PUBMED   ScienceOn
20 Sisodia SS, St George-Hyslop PH. Gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3: 281−290, 2002   DOI   PUBMED   ScienceOn
21 Jeng US, Lin TL, Lin JM, Ho DL. Contrast variation SANS for the solution structure of the $\beta$-amyloid peptide1-40 influenced by SDS surfactants. Physica B 385−386: 865−867, 2006   DOI   ScienceOn
22 Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. Amyloid- beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67: 1216−1228, 1994   DOI   PUBMED   ScienceOn
23 Howlett DR, Jennings KH, Lee DC, Clark MS, Brown F, Wetzel R, Wood SJ, Camilleri P, Roberts GW. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4: 23−32, 1995   DOI   PUBMED   ScienceOn
24 Soreghan B, Kosmoski J, Glabe C. Surfactant properties of Alzheimer's Abeta peptides and the mechanism of amyloid aggregation. J Biol Chem 269: 28551−28554, 1994   PUBMED   ScienceOn
25 Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science 265: 1464−1467, 1994   DOI   PUBMED   ScienceOn
26 Gschwind M, Huber G. Apoptotic cell death induced by beta-amyloid 1-42 peptide is cell type dependent. J Neurochem 65: 292−300, 1995   DOI   PUBMED   ScienceOn
27 Wang SS, Chen YT, Chou SW. Inhibition of amyloid fibril formation of beta-amyloid peptides via the amphiphilic surfactants. Biochim Biophys Acta 1741: 307−313, 2005   DOI   PUBMED
28 Sabate R, Estelrich J. Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis. Langmuir 21: 6944−6949, 2005b   DOI   PUBMED   ScienceOn
29 Seilheimer B, Bohrmann B, Bondolfi L, M$\ddot{u}$ller F, Stuber D, Dobeli H. The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. J Struct Biol 119: 59−71, 1997   DOI   PUBMED   ScienceOn
30 Koh JY, Yang LLY, Cotman CW. Beta-amyloid protein increases vulnerability of cultured neurons to excitotoxins. Brain Res 533: 315−320, 1990   DOI   PUBMED   ScienceOn
31 Wood SJ, Maleeff B, Hart T, Wetzel R. Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. J Mol Biol 256: 870−877, 1996b   DOI   PUBMED   ScienceOn
32 Nowick JS, Lam KS, Khasanova TV, Kemnitzer WE, Maitra S, Mee HT, Liu R. An unnatural amino acid that induces beta-sheet folding and interaction in peptides. J Am Chem Soc 124: 4972−4973, 2002   DOI   PUBMED   ScienceOn
33 Sabate R, Estelrich J. Evidence of the existence of micelles in the fibrillogenesis of beta-amyloid peptide. J Phys Chem B 109: 11027−11032, 2005a   DOI   PUBMED   ScienceOn
34 Halverson K, Fraser PE, Kirschner DA, Lansbury PT Jr. Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry 29: 2639−2644, 1990   DOI   PUBMED   ScienceOn
35 Lowe TL, Strzelec A, Kiessling LL, Murphy RM. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 40: 7882−7889, 2001   DOI   PUBMED   ScienceOn
36 Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 273: 7185−7188, 1998   DOI   PUBMED   ScienceOn
37 Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69: 1622−1634, 2007   DOI   PUBMED   ScienceOn
38 Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2: 539−547, 2003   DOI   ScienceOn
39 Rangachari V, Reed DK, Moore BD, Rosenberry TL. Secondary structure and interfacial aggregation of amyloid-beta (1-40) on sodium dodecyl sulfate micelles. Biochemistry 45: 8639−8648, 2006   DOI   PUBMED   ScienceOn
40 Marcinowski KJ, Shao H, Clancy EL, Zagorski MG. Solution structure model of residues 1-28 of the amyloid beta peptide when bound to micelles. J Am Chem Soc 120: 11082−11091, 1998   DOI   ScienceOn
41 Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord 4: 383−403, 2005   DOI   ScienceOn
42 Jarrett JT, Berger EP, Lansbury Jr. PT. The carboxy terminus of the $\beta$-amyloid protein is critical for the seeding of amyloid formation: implication for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693−4697, 1993   DOI   PUBMED   ScienceOn
43 Khandogin J, Brooks III CL. Linking folding with aggregation in Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci USA 104: 16880−16885, 2007   DOI   ScienceOn
44 Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB. On the nucleation of amyloid beta-protein monomer folding. Protein Sci 14: 1581−1596, 2005   DOI   ScienceOn
45 Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA 91: 12243−12247, 1994   DOI   ScienceOn
46 Mook-Jung I, Joo I, Sohn S, Kwon HJ, Huh K, Jung MW. Estrogen blocks neurotoxic effects of beta-amyloid (1-42) and induces neurite extension in B103 cells. Neurosci Lett 235: 101−104, 1997   DOI   PUBMED   ScienceOn
47 Rochet JC Jr, Lansbury PT. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10: 60−68, 2000   DOI   PUBMED   ScienceOn
48 Salomon AR, Marcinowski KJ, Friedland RW, Zagorski MG. Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 35: 13568−13578, 1996.   DOI   PUBMED   ScienceOn
49 Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16: 921−932, 1996   DOI   PUBMED   ScienceOn
50 Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1: 143−148, 1995   DOI   PUBMED   ScienceOn
51 Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. On the nucleation and growth of amyloid beta-protein fibrils: Detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 93: 1125−1129, 1996   DOI   ScienceOn
52 Pike CJ, burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by $\beta$-amyloid peptides in vitro: the role of peptide assembly state. J Neruosci 13: 1676−1687, 1993   ScienceOn
53 Lizard G, Fournel S, Genestier L, Dhedin N, Chaput C, Flacher M, Mutin M, Panaye G, Revillard JP. Kinetics of plasma membrane and mitochondrial alterations in cells undergoing apoptosis. Cytometry 21: 275−283, 1995   DOI   PUBMED   ScienceOn
54 Ban T, Hoshino M, Takahashi S, Hamada D, Hasegawa K, Naiki H, Goto Y. Direct observation of Abeta amyloid fibril growth and inhibition. J Mol Biol 344: 757−767, 2004   DOI   PUBMED   ScienceOn